CARNEYS POINT, NJ--(Marketwired - July 13, 2015) - CannaPharmaRx, Inc. (OTCQB: CPMD), an early stage pharmaceutical company whose purpose is to advance cannabinoid research and discovery (the "Company"), will be exhibiting and speaking at The MoneyShow in San Francisco, CA. The MoneyShow will be held at the San Francisco Marriott Marquis from Thursday, July 16^th through Saturday, July 18^th. CannaPharmaRx will be exhibiting at Salon 7-8.

Mr. Mathew Sherwood, VP of Product Development at CannaPharmaRx, will be speaking as part of two workshops at the event:

On Saturday, July 18^th, from 9:00am to 9:45am, Mr. Sherwood, alongside Mr. Scott Greiper of Viridian Capital Advisors and other cannabis companies will be discussing the opportunities and challenges of investing in publicly traded cannabis stocks, as well as how CannaPharmaRx differentiates itself as a leader in the industry, as part of the "Investing in the Next Big High-Growth Sector Part II" session. Click here for more information on this session.

On Saturday, July 18^th, from 12:00pm to 4:00pm, Mr. Sherwood will be part of a panel of companies discussing investments in biotech businesses around the cannabis industry and other topics during the "Cannabis Investing Symposium." Click here for more information on this session.

The MoneyShow is the top finance and investor conference in the nation. Featuring renowned experts such as Mr. Steve Forbes, editor-in-chief of Forbes magazine, The MoneyShow serves as a premier platform for acquiring advice, information, and perspective on the challenging and ever-changing global investment landscape.

Click the picture to the right for more information on The MoneyShow San Francisco.

About CannaPharmaRx, Inc.
CannaPharmaRx, Inc. is an early-stage pharmaceutical company whose purpose is to advance cannabinoid research and discovery using proprietary formulation and drug delivery technology currently in development. Cannabinoids are a class of chemicals that, once ingested, are active in humans and animals through the "endocannabinoid system" -- one of the most widely expressed system of receptors in the human body. CannaPharmaRx is currently focused on targeting disease states where its delivery systems can have optimal impact with therapeutic differentiation among alternative cannabinoid therapies, including: neurological disorders, oncology, infectious disease, pain management, inflammatory disease, gastrointestinal disorders and ophthalmology. For more information, please visit www.CannaPharmaRx.com.

Forward-Looking Statements
Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as "anticipate," "believe," "forecast," "estimated," and "intend" among others. These forward-looking statements are based on CannaPharmaRx's current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to: our ability to satisfy the closing conditions to the proposed merger, substantial competition; our ability to continue as a going concern; our need for additional financing; uncertainties of patent protection and litigation; clinical trials involve a lengthy and expensive process with an uncertain outcome, and results of earlier studies and trials may not be predictive of future trial results; uncertainties of government or third party payer reimbursement; limited sales and marketing efforts and dependence upon third parties; and risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations. As with any pharmaceutical products under development, there are significant risks in the development, regulatory approval and commercialization of new products. There are no guarantees that the merger or other matters discussed in this press release will be completed or successful. CannaPharmaRx does not undertake any obligation to update or revise any forward-looking statement. Investors should read the risk factors set forth in CannaPharmaRx's Annual Report on Form 10-K for the year ended December 31, 2014 and other periodic reports filed with the Securities and Exchange Commission.

Image Available: http://www.marketwire.com/library/MwGo/2015/7/13/11G047357/Images/The_MoneyShow_image-398756168790.jpg